(1-34) Parathyroid Hormone Infusion Acutely Lowers Fibroblast Growth Factor 23 Concentrations in Adult Volunteers

被引:24
|
作者
Gutierrez, Orlando M. [1 ]
Smith, Kelsey T. [1 ]
Barchi-Chung, Allison [1 ]
Patel, Neha M. [1 ]
Isakova, Tamara [1 ]
Wolf, Myles [1 ]
机构
[1] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Dept Med, Miami, FL 33136 USA
基金
美国国家卫生研究院;
关键词
CHRONIC KIDNEY-DISEASE; BONE; MORTALITY; FIBROBLAST-GROWTH-FACTOR-23; PTH; HYPERPARATHYROIDISM; HEMODIALYSIS; EXPRESSION; PHOSPHATE; FGF23;
D O I
10.2215/CJN.06240611
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives Fibroblast growth factor 23 (FGF23) regulates phosphorus and vitamin D metabolism. Parathyroid hormone (PTH) infusion for 24 hours stimulated FGF23 secretion in healthy volunteers. The extent to which this was due to a direct stimulatory effect of PTH versus an indirect effect of increasing 1,25-dihydroxyvitamin D [1,25(OH)(2)D] levels was unclear. Design, setting, participants, & measurements Changes in FGF23 in 26 adults undergoing 6-hour (1-34) PTH infusion were examined, focusing particularly on the effects of PTH on FGF23 in the early period of infusion before sustained increases in 1,25(OH)(2)D. Results FGF23 levels declined in parallel with serum phosphate during infusion (P<0.05 for both), with both analytes decreasing within the first hour and reaching their respective nadirs at 6 hours. These changes were observed despite no change in 1,25(OH())2D levels during the first hour and a significant increase in 1,25(OH)(2)D from baseline after 6 hours (P<0.001). There were no differences in these responses by race. However, modest racial differences in the phosphaturic response to (1-34) PTH were observed (P=0.04 for interaction), with a higher rate of increase in fractional phosphate excretion in blacks than in whites. Conclusions During short-term (1-34) PTH infusion, FGF23 levels decreased in parallel with serum phosphate levels and despite significant increases in 1,25(OH)(2)D. When coupled with the results of prior longer-term infusion studies, these findings suggest that acute increases in PTH initially act to suppress FGF23 secretion, perhaps to mitigate urinary phosphate losses, before the stimulatory effect of 1,25(OH)(2)D on FGF23 eventually begins to predominate. Clin J Am Soc Nephrol 7: 139-145, 2012. doi: 10.2215/CJN.06240611
引用
收藏
页码:139 / 145
页数:7
相关论文
共 50 条
  • [31] Bone Health and Linear Growth in Children With Familial Hypoparathyroidism Treated With Human Parathyroid Hormone 1-34
    Winer, Karen K.
    Zemel, Babette S.
    Kelly, Andrea
    Reynolds, James C.
    Pechacek, Joseph
    Webb, Taura
    Hans, Didier
    Lionakis, Michail S.
    Kalkwarf, Heidi J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025,
  • [32] SKELETAL EFFECTS OF LONG-TERM INFUSION OF PHYSIOLOGICAL DOSES OF 1-34 PARATHYROID-HORMONE (PTH) ON BONE
    MALLUCHE, HH
    SHERMAN, D
    HEALY, M
    NORMAN, AW
    MASSRY, SG
    CLINICAL RESEARCH, 1980, 28 (01): : A81 - A81
  • [33] Parathyroid hormone-(1-34) enhances aggrecan synthesis via an insulin-like growth factor-I pathway
    Harvey, AK
    Yu, XP
    Frolik, CA
    Chandrasekhar, S
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (33) : 23249 - 23255
  • [34] Intermittently administered parathyroid hormone 1-34 reverses bone loss and structural impairment in orchiectomized adult rats
    Gabet, Y
    Kohavi, D
    Müller, R
    Chorev, M
    Bab, I
    OSTEOPOROSIS INTERNATIONAL, 2005, 16 (11) : 1436 - 1443
  • [35] RESPONSE OF THE PARATHYROID-GLAND TO INFUSION OF HUMAN PARATHYROID HORMONE-(1-34) [PTH-(1-34)] - DEMONSTRATION OF SUPPRESSION OF ENDOGENOUS SECRETION USING IMMUNORADIOMETRIC INTACT PTH-(1-84) ASSAY
    COSMAN, F
    SHEN, V
    HERRINGTON, B
    LINDSAY, R
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (06): : 1345 - 1351
  • [36] Parathyroid hormone is an independent predictor of fibroblast growth factor-23 in healthy men:: MROS Sweden
    Marsell, R.
    Grundberg, E.
    Krajisnik, T.
    Westerberg, P.
    Mallmin, H.
    Karlsson, M.
    Mellstrom, D.
    Orwoll, E.
    Ohlsson, C.
    Jonsson, K. B.
    Ljunggren, O.
    Larsson, T.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S44 - S45
  • [37] Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease
    Galvao, Joao F. de Brito
    Nagode, Larry A.
    Schenck, Patricia A.
    Chew, Dennis J.
    JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE, 2013, 23 (02) : 134 - 162
  • [38] Vitamin D-Parathyroid Hormone-Fibroblast Growth Factor 23 Axis and Cardiac Remodeling
    Deng, Cuiyun
    Wu, Yihang
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2025, 25 (01) : 25 - 36
  • [39] Fibroblast Growth Factor 23, but not Parathyroid Hormone, Is Associated With Urinary Phosphate Regulation in Patients on Peritoneal Dialysis
    Yamada, Shunsuke
    Tsuruya, Kazuhiko
    Tokumoto, Masanori
    Yoshida, Hisako
    Hasegawa, Shoko
    Tanaka, Shigeru
    Eriguchi, Masahiro
    Nakano, Toshiaki
    Masutani, Kosuke
    Ooboshi, Hiroaki
    Kitazono, Takanari
    THERAPEUTIC APHERESIS AND DIALYSIS, 2015, 19 (01) : 73 - 80
  • [40] Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers
    Chu, N. N.
    Li, X. N.
    Chen, W. L.
    Xu, H. R.
    PHARMAZIE, 2007, 62 (11): : 869 - 871